1. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter phase II trial of two different schedules of irinotecan combined to capecitabine as first line treatment in metastatic colorectal cancer. Cancer 100: 279–287
2. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084–2091
3. Chen E, Welch S, Krzyzanowska M, MacKay H, Knox J, Feld R, Petronis J, Blatter C, Wang L, Moore MJ (2009) A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) [abstract e15019]. J Clin Oncol ASCO Annu Meet Proc 27: e15019
4. Ducreux M, Adenis A, Mendiboure J, François E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T, Institut Gustave Roussy, Villejuif, France; Centre Oscar Lambret, Lille, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Centre Georges-François Leclerc, Dijon, France; Centre Val d’Aurelle, Montpellier, France; Institut Curie, Paris, France; FNCLCC, Paris, France; Centre Alexis Vautrin, Nancy, France (2009) Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) [abstract 4086]. J Clin Oncol ASCO Annu Meet Proc 27: 4086
5. Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689–690